Biotech Values

[DewDiligence]

…therefore, I think docs are likely to wait for more data (including outcomes data).

No argument there—the disappointing sales numbers for Tekturna speak for themselves. However, if docs are waiting for “pure” hypertension outcomes data showing a reduction in mortality or MACE, they will be waiting a long time!